Overall, these findings suggest that Resvega not only limits VEGF production through direct interaction with key signaling pathways but also alters the dynamics of transcription factor localization, contributing to its potential as a therapeutic agent in managing AMD (Figure 4). Here, VEGFA is linked to age-related macular degeneration.